Answers are grounded in this paper and cite their sources.
= 23), respectively. There is a need for standardized reporting of CD19 antigen status in the setting of relapse following novel immunotherapies to inform clinical practice.
No takes yet. Share an insight, caveat, or question.
Locatelli et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: